The Trump administration is attempting to slash NIH funding, terminate research grants, and reduce the agency’s workforce.

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.

(HealthDay News) — Weeks after ordering staff back to the office, the US Food and Drug Administration (FDA) is letting some employees work from home again, The Associated Press reported. The move ...

On April 1, the Trump administration slashed the organization that supported that research — the Agency for Healthcare ...

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

Layoffs across health agencies have eliminated workers who handled Freedom of Information Act requests at the CDC, FDA, and NIH.

Ensuring timely completion of post-approval studies and enforcing appropriate regulatory actions based on negative trial results is necessary to minimize patient exposure to ineffective and ...

The US Senate has confirmed the appointment of Mehmet Oz, MD, to head the Centers for Medicare & Medicaid Services.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

Some recent cuts at government health agencies may be reversed, including a key program that tracks lead exposure in children, the HHS secretary said last week.